Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.60 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CTSG | P08311 | 1/20 | 0.48 |
| ▸ | CMA1 | P23946 | 1/20 | 0.48 |
| ▸ | KDM4A | O75164 | 1/20 | 0.47 |
| ▸ | KDM5A | P29375 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.47 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1008547 | 1.00 | PLA2G2A (0.60) | PLA2G2AITGB3ITGA2BALOX5HDAC1 | |
| SCHEMBL1005598 | 1.00 | PLA2G2A (0.60) | PLA2G2AITGB3ITGA2BALOX5HDAC1 | |
| SCHEMBL1007375 | 1.00 | PLA2G2A (0.60) | PLA2G2AITGB3ITGA2BALOX5HDAC1 | |
| SCHEMBL1007374 | 1.00 | PLA2G2A (0.60) | PLA2G2AITGB3ITGA2BALOX5HDAC1 | |
| SCHEMBL1006714 | 1.00 | PLA2G2A (0.60) | PLA2G2AITGB3ITGA2BALOX5HDAC1 | |
| SCHEMBL1005630 | 1.00 | PLA2G2A (0.60) | PLA2G2AITGB3ITGA2BALOX5HDAC1 | |
| SCHEMBL4294010 | 1.00 | PLA2G2A (0.60) | PLA2G2AITGB3ITGA2BALOX5HDAC1 | |
| SCHEMBL1008447 | 1.00 | PLA2G2A (0.60) | PLA2G2AITGB3ITGA2BALOX5HDAC1 | |
| SCHEMBL1006715 | 1.00 | PLA2G2A (0.60) | PLA2G2AITGB3ITGA2BALOX5HDAC1 | |
| SCHEMBL1008526 | 1.00 | PLA2G2A (0.60) | PLA2G2AITGB3ITGA2BALOX5HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268606-B1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | claimed |
| CN-101952243-B | 4-dimethylaminobutyric acid derivatives | HOFFMANN LA ROCHE | 2014-07-16 | — | — | CN | claimed |
| US-8344027-B2 | 4-dimethylaminobutyric acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-01 | — | — | US | claimed |
| US-20120289554-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | ANDJELKOVIC MIRJANA (CH) | 2012-11-15 | — | — | US | claimed |
| CN-101952243-A | 4-dimethylaminobutyric acid derivatives | HOFFMANN LA ROCHE | 2011-01-19 | — | — | CN | claimed |
| EP-2268606-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-01-05 | — | — | EP | claimed |
| WO-2009132978-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-05 | — | — | WO | claimed |
| US-20090270505-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-10-29 | — | — | US | claimed |
| EP-2280935-B1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-10-15 | — | — | EP | disclosed |
| EP-2268606-B1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | disclosed |
| CN-101952243-B | 4-dimethylaminobutyric acid derivatives | HOFFMANN LA ROCHE | 2014-07-16 | — | — | CN | disclosed |
| US-8673946-B2 | 4-trimethylammonio-butyrates as CPT2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| CN-102015626-B | 4-trimethylammonio-butyrates as CPT2 inhibitors | HOFFMANN LA ROCHE | 2013-12-11 | — | — | CN | disclosed |
| US-20130030033-A1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2013-01-31 | — | — | US | disclosed |
| CN-101952243-A | 4-dimethylaminobutyric acid derivatives | HOFFMANN LA ROCHE | 2011-01-19 | — | — | CN | disclosed |
| EP-2268606-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009132979-A1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009132978-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270505-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270500-A1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270505-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | CPT1B, CPT1A, CPT2 | PLA2G2A 978/4885ITGB3 4217/4885ITGA2B 2298/4885 |
| US-20090270500-A1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | CPT1A, CPT1B, CPT2 | PLA2G2A 1854/4885ITGB3 3479/4885ITGA2B 2337/4885 |
| US-20120289554-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | CPT1B, CPT1A, CPT2 | PLA2G2A 978/4885ITGB3 4217/4885ITGA2B 2298/4885 |
| US-20130030033-A1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | CPT1A, CPT1B, CPT2 | PLA2G2A 1854/4885ITGB3 3479/4885ITGA2B 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.